Brady Huggett

DrugAbuse Sciences' Product Shows Benefit In Phase III Trial

Jan. 7, 2003

By Brady Huggett

Atrix Licenses Japanese Eligard Rights To Sosei In $30M Deal

Jan. 7, 2003

By Brady Huggett

TolerRx Closes $35M Series C, Collaborates With Genentech

Jan. 6, 2003

By Brady Huggett

TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today)

TolerRx Closes $35M Series C, Collaborates With Genentech

Jan. 6, 2003

By Brady Huggett

TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today)

EntreMed Finds Relief Through $27M Celgene Thalidomide Deal

Jan. 3, 2003

By Brady Huggett

EntreMed Inc. managed to resolve ongoing litigation, bring in the necessary cash to fund operations for some time and help alleviate issues surrounding a potential Nasdaq delisting through one move - the signing of a deal valued at about $27 million with Celgene Corp. for EntreMed's thalidomide analogue program. (BioWorld Today)

EntreMed Finds Relief Through $27M Celgene Thalidomide Deal

Jan. 3, 2003

By Brady Huggett

EntreMed Inc. managed to resolve ongoing litigation, bring in the necessary cash to fund operations for some time and help alleviate issues surrounding a potential Nasdaq delisting through one move - the signing of a deal valued at about $27 million with Celgene Corp. for EntreMed's thalidomide analogue program. (BioWorld Today)